IGM Biosciences Inc Review of IGM-2323 Data Presented at the 62nd Annual ASH Meeting - Conference Call Transcript
Good day, everyone, and welcome to the IGM Biosciences conference call and webcast to review the IGM-2323 data presented today at the 62nd Annual ASH meeting. Today's call is being recorded. (Operator Instructions)
At this time, I would now like to turn the call over to Fred Schwarzer, Chief Executive Officer.
Thank you, operator, and welcome to all of you joining us today. I would like to thank you for taking time on your Saturday to join this presentation. All of us at IGM have been eagerly awaiting this day for 15 months ever since we dosed our first patient last year, and we are very excited and pleased to share our excellent initial efficacy and safety data from the clinical trial of IGM-2323.
This presentation contains certain forward-looking statements. And we must advise you that these forward-looking statements are subject to many factors which are beyond our control, and they should not be relied upon as predictions of future events. In this regard, we direct
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
